CYP2C9 rs1057910 Genotype and Its Association with Paraclinical Characteristics in Gout Patients in the Northeast Region of Vietnam

BACKGROUND: Celecoxib and lesinurad are medications used in the management of gout, and their metabolism is significantly influenced by genetic variations in the CYP2C9 enzyme. CYP2C9*3 (rs1057910) is associated with reduced CYP2C9 activity. This study investigated the association between CYP2C9 rs1057910 genotype and paraclinical characteristics in gout patients from the Northeast region of Vietnam.METHODS: A total of 139 gout patients were recruited and their paraclinical characteristics including red blood cell, hemoglobin, hematocrit, white blood cell, neutrophil, lymphocyte, platelet, glucose, urea, creatinine, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were collected. The CYP2C9 rs1057910 genotypes were identified by Sanger sequencing method of PCR products, analyzed with BioEdit software, and verified using the NCBI dbVar database. Statistical analyses were performed using SPSS.RESULTS: The cohort was predominantly male (93.5%), with female patients showing a significantly higher mean age (70.33±10.64 years) than males (51.81±14.93 years, p<0.001). This study showed significant positive correlations between uric acid concentration, creatinine (r=0.201, p=0.018) and platelet count (r=0.169, p=0.046). The wild-type homozygous CYP2C9*1/*1 genotype was found in 92.09% of patients; the CYP2C9*1/*3 and CYP2C9*3/*3 genotypes were identified in 7.19% and 0.72%, respectively. No significant differences in most paraclinical parameters were observed between genotype groups, except for HDL-C levels, which were significantly higher in CYP2C9*3 carriers (p=0.000).CONCLUSION: This study showed that the CYP2C9*3 carrier is significantly associated with higher HDL-C levels compared to the CYP2C9*1/*1 in gout patients. This finding suggests that the CYP2C9*3 variant may influence lipid metabolism in a way that promotes a more favorable lipid profile, which are considered protective against cardiovascular disease.KEYWORDS: CYP2C9 gene, CYP2C9*3, CYP2C9 rs1057910 genotype, gout patients, paraclinical characteristics